Effects of phosphate on vascular function under normal conditions and influence of the uraemic state

Cardiovascular Research

Volumn 96, Issue 1, 2012, Pages 130-139

  Six, Isabelle ^a   Maizel, Julien ^a,b   Barreto, Fellype C ^a   Rangrez, Ashraf Y ^a   Dupont, Sébastien ^a   Slama, Michel ^a,b   Tribouilloy, Christophe ^a,b   Choukroun, Gabriel ^a,b   Mazière, Jean Claude ^a,b   Bode Boeger, Stefanie ^c   Kielstein, Jan T ^d   Drüeke, Tilman B ^a   Massy, Ziad A ^a,b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chronic kidney disease; Endothelium; Mouse; Phosphate; Sevelamer HCl

Indexed keywords

ACETYLCHOLINE; DIMETHYLTHIOUREA; HYDROCHLORIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATE; PLACEBO; REACTIVE OXYGEN METABOLITE; SEVELAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL STIFFNESS; ARTICLE; BODY WEIGHT; CELL LOSS; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC DYSFUNCTION; DIET; DRUG ACTIVITY; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE RELAXATION; HEMATOCRIT; HUMAN; HUMAN CELL; KIDNEY FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULSE WAVE; UREMIA; VASCULAR RING; VASOCONSTRICTION;

ANIMALS; CELLS, CULTURED; CHELATING AGENTS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEART DISEASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPERPHOSPHATEMIA; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; PHOSPHATES; PHOSPHORUS, DIETARY; POLYAMINES; PULSE WAVE ANALYSIS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; UREMIA; VASCULAR DISEASES;

EID: 84866644860     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs240     Document Type: Article

References (31)

1. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
2. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17.
3. Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 2003;14:S300-S304.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
5. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005; 112:2627-2633.
6. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-885.
7. Onufrak SJ, Bellasi A, Shaw LJ, Herzog CA, Cardarelli F, Wilson PW et al. Phosphorus levels are associated with subclinical atherosclerosis in the general population. Atherosclerosis 2008;199:424-431.
8. Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009;20:1504-1512.
9. Ellam T, Wilkie M, Chamberlain J, Crossman D, Eastell R, Francis S et al. Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2011;31:1988-1990.
10. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
11. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005;112:2875-2882.
12. Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 2007;18:122-130.
13. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
14. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-1824.
15. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA et al., CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-965.
16. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-441.
17. Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moysés RM, Jorgetti V. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004;66:2237-2244.
18. Amann K, Tö rnig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003;63:1296-1301.
19. Maizel J, Six I, Slama M, Tribouilloy C, Sevestre H, Poirot S et al. Mechanisms of aortic and cardiac dysfunction in uremic mice with aortic calcification. Circulation 2009;119: 306-313.
20. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005;16:109-116.
21. Martens-Lobenhoffer J, Bode-Böger SM. Fast and efficient determination of arginine, symmetric dimethylarginine, and asymmetric dimethylarginine in biological fluids by hydrophilic-interaction liquid chromatography-electrospray tandem mass spectrometry. Clin Chem 2006;52:488-493.
22. Vanhoutte PM, Boulanger CM. Endothelium-dependent responses in hypertension. Hypertens Res 1995;18:87-98.
23. Yang D, Félétou M, Boulanger CM, Wu HF, Levens N, Zhang JN et al. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol 2002;136:104-110.
24. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998;53:1748-1754.
25. Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, Lang D et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 2008;294:F1381-F1387.
26. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010;24:3562-3571.
27. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
28. Nikolov IG, Joki N, Maizel J, Lacour B, Drüeke TB, Massy ZA. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl 2006;105:S16-S23.
29. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T et al. Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008;3: 61-68.
30. Sonikian MA, Pani IT, Iliopoulos AN, Koutala KG, Marioli SI, Vlassopoulos DA. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005;27:143-147.
31. Li N, Karin M. Is NF-kappaB the sensor of oxidative stress? FASEB J 1999;13: 1137-1143.